Archived

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

Federal funding opportunity RFA-DA-24-038 from National Institutes of Health (Department of Health and Human Services).

Posted: April 18, 2023
Closed: February 14, 2025
Award ceiling: $300,000
Cost sharing: No
Instrument: Grant
Assistance listing: 93.279
Category: Education, Health
Archives: March 22, 2025

Program funding history

Awards made under Assistance Listing 93.279 across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $1.5B
FY2026 obligated: $1.5B
FY2027 (to date) obligated: $0
Awards in window: 4,922

Top recipients: Yale Univ, The Johns Hopkins University, University of California, San Diego, University of Pittsburgh - of the Commonwealth System of Higher Education, Regents of the University of Michigan

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is archived. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

Who can apply

Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
PAR-25-100 · National Institutes of Health · closes May 7, 2027
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
PAR-27-053 · National Institutes of Health · closes June 16, 2028
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
PAR-25-446 · National Institutes of Health · closes August 21, 2028
Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
PAR-27-026 · National Institutes of Health · closes September 25, 2028
NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
PAR-24-089 · National Institutes of Health · closes November 13, 2026
HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)
RFA-DA-28-011 · National Institutes of Health · closes January 26, 2027

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing